Infectious Disease · Public Health · 2 h ago
Six Cryptococcus gattii infections identified in Nova Scotia, 2016–2024
A retrospective descriptive analysis identified six species-confirmed Cryptococcus gattii infections in Nova Scotia from 2016 through 2024. Five western-zone isolates were genotype VGIIb; four patients reported no travel outside the province, supporting—but not confirming—local acquisition.
- Six confirmed infections were identified over nine years.
- Five western-zone isolates were genotype VGIIb.
- Four western-zone patients reported no out-of-province travel.
- Environmental sampling was not conducted.
Researchers reviewed clinical and public health records to identify confirmed C. gattii infections in Nova Scotia from January 2016 through December 2024. Six cases met the species-confirmed case definition. Isolates underwent molecular typing; three additional cryptococcal antigen–positive cases were excluded because species identification was unavailable.
Five cases occurred in western Nova Scotia, and all five isolates were genotype VGIIb. Four patients reported no travel outside the province; one had traveled to British Columbia. The sixth case, in eastern Nova Scotia, was genotype VGI, and the patient had previously lived in South Africa, leaving the likely place of acquisition uncertain. All six patients had central nervous system involvement, two also had pulmonary involvement, and five were presumed immunocompetent. All were hospitalized; one required intensive care and one died.
The findings, alongside a previous detection of a VGIIb-like strain in a Nova Scotia deer, suggest possible regional endemicity. However, the small case series, retrospective exposure data, incomplete ascertainment, and lack of environmental sampling mean local acquisition and a local reservoir were not directly confirmed. The article is an early-release version; the authors note that C. gattii was added to Nova Scotia’s notifiable disease list in 2026.
In practice
In Nova Scotia, clinicians evaluating compatible central nervous system disease may consider C. gattii even when a patient has no recognized immunocompromising condition: all six confirmed patients in this series had CNS involvement, and five were presumed immunocompetent. This small, retrospective series does not establish prevalence or prove local acquisition, and environmental sampling was not performed. It supports diagnostic consideration in context, but does not establish a change to testing or treatment practice.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Emerging Infectious Diseases: Endemic Cryptococcus gattii Infections, Nova Scotia, Canada, 2016–2024 ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.